Camidge D.R.Kim H.R.Ahn M.-J.CHIH-HSIN YANGHan J.-Y.Hochmair M.J.Lee K.H.Delmonte A.Garcia Campelo M.R.Kim D.-W.Griesinger F.Felip E.Califano R.Spira A.I.Gettinger S.N.Tiseo M.Lin H.M.Liu Y.Vranceanu F.Niu H.Zhang P.Popat S.2022-08-102022-08-1020211556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116813235&doi=10.1016%2fj.jtho.2021.07.035&partnerID=40&md5=72fb91a198dc44ff82738e8aaca778bfhttps://scholars.lib.ntu.edu.tw/handle/123456789/616497[SDGs]SDG3Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trialjournal article10.1016/j.jtho.2021.07.035345374402-s2.0-85116813235